{"id":"W2918407168","doi":"10.1016/s2213-8587(19)30066-x","title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":367,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Manitoba; Mount Sinai Hospital","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Type 2 diabetes; Placebo; Dulaglutide; Internal medicine; Diabetes mellitus; Randomized controlled trial; Concomitant; Clinical trial; Exenatide; Liraglutide; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009386988,0.00049657,0.0019043,0.0003856195,0.00008385979,0.00005251369,0.0004627237,0.0001244082,0.0005126961],"category_scores_gemma":[0.0006475138,0.0003198491,0.0002783139,0.0004661207,0.0001116198,0.00007002243,0.0001813656,0.0004571088,0.001416822],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002030897,"about_ca_system_score_gemma":0.0001111763,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002596316,"about_ca_topic_score_gemma":0.00002038321,"domain_scores_codex":[0.9958256,0.0004696508,0.0006064998,0.0006705877,0.0003703593,0.002057316],"domain_scores_gemma":[0.9969357,0.001591162,0.0001880957,0.001033572,0.00008702567,0.0001644055],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8760207,0.001200569,0.050915,0.0001219285,0.001738361,0.0001107223,0.0005276418,0.0001508082,0.009858521,0.002834693,0.01772853,0.03879254],"study_design_scores_gemma":[0.9236798,0.01015401,0.004841696,0.0002018141,0.000260825,0.000001795885,0.0002017285,0.0001469077,0.009544536,0.0007662314,0.04975894,0.0004417213],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9630746,0.001341301,4.08454e-7,0.01145476,0.001172581,0.01084994,0.000006687227,0.0001978006,0.0119019],"genre_scores_gemma":[0.979902,0.000329231,0.00009725868,0.01044712,0.0009593444,0.002084199,0.00003159856,0.00006976811,0.006079516],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04765911,"threshold_uncertainty_score":0.9999254,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0164886080544158,"score_gpt":0.2803438125386376,"score_spread":0.2638552044842218,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}